PBYI - Puma Biotechnology up 15% after quarterly earnings beats

Shares of Puma Biotechnology (NASDAQ:PBYI) have raced 15% higher in post-market trading after posting Q4 2021 results that beat on the top and bottom lines. The company swung to a quarterly net gain of $4.2M from a net loss of $15M in the prior year period ($0.10 per share basic by diluted in Q4 2021 vs -$0.38 Q4 2020). Revenue of $55.4M in the quarter was a 5.3% year-over-year increase. Total operating costs and expenses fell 24% year over year to $48.6M. The company ended the year with $82.1M in cash. In January, Puma's (PBYI) breast cancer therapy Nerlynx (neratinib) was included in a National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology update.

For further details see:

Puma Biotechnology up 15% after quarterly earnings beats